GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Talis Biomedical Corp (OTCPK:TLIS) » Definitions » Median PS Value

TLIS (Talis Biomedical) Median PS Value : $0.00 (As of Apr. 06, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Talis Biomedical Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Talis Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.165. Talis Biomedical's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2025-04-06), Talis Biomedical's share price is $1.555. Talis Biomedical's Median PS Value is $0.00. Therefore, Talis Biomedical's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Talis Biomedical's Median PS Value or its related term are showing as below:

TLIS's Price-to-Median-PS-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.74
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Talis Biomedical Median PS Value Historical Data

The historical data trend for Talis Biomedical's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talis Biomedical Median PS Value Chart

Talis Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial - - - - -

Talis Biomedical Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Talis Biomedical's Median PS Value

For the Medical Devices subindustry, Talis Biomedical's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Talis Biomedical's Price-to-Median-PS-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Talis Biomedical's Price-to-Median-PS-Value falls into.


;
;

Talis Biomedical Median PS Value Calculation

Talis Biomedical's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.165*0
=0.00

10-Year Median PS Ratio is 0.
Talis Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.165.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Talis Biomedical  (OTCPK:TLIS) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Talis Biomedical's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=1.555/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Talis Biomedical Median PS Value Related Terms

Thank you for viewing the detailed overview of Talis Biomedical's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Talis Biomedical Business Description

Traded in Other Exchanges
N/A
Address
1375 West Fulton Market, Suite 700, Chicago, IL, USA, 60607
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
Executives
Andrew A Lukowiak officer: President, other: Chief Scientific Officer 1639 WINDEMERE DRIVE, SAN MARCOS CA 92078
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Rebecca Markovich officer: Interim CFO CARS.COM INC., 300 S. RIVERSIDE PLAZA, SUITE 1000, CHICAGO IL 60606
Raymond Cheong director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian J Blaser director, officer: President and CEO 561 CIRCLE LANE, LAKE FOREST IL 60045
Ramesh Ramakrishnan officer: Sr. Vice President, R&D 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Randal W Scott director 171 MAIN STREET #225, LOS ALTOS CA 94022
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Kimberly J Popovits director 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Moody John Roger Jr officer: Chief Financial Officer 4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062